


Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

GSK to commercialise Tebipenem HBr in all territories, except Japan and certain other Asian countries

Spero Therapeutics



Tebipenem pivoxil hydrobromide (tebipenem HBr), a late-stage oral carbapenem antibiotic, to potentially treat complicated UTIs, including pyelonephritis (09/22)

GlaxoSmithKline



- \$66M Upfront Payment
- \$150M Total Commercial Milestone Payments
- \$150M Total Dev Milestone Payments
- \$225M Total Sales Milestone Payments

Low-single digit to low-double digit (if sales exceed \$1B) tiered royalties on net product sales



GSK to purchase \$9 million in shares of Spero common stock

TAGS

This is a selection of the tags about this deal. For all tags related to this deal, log into BioSciDB

1.174. “Territory” means (a) with respect to Spero, the Excluded Territory; or (b) with respect to GSK, the GSK Territory, as applicable.

1.87. “GSK Territory” means worldwide, excluding the Excluded Territory (subject to adjustment pursuant to Section 2.11(b)).

1.56. “Excluded Territory” means Japan, Bangladesh, Brunei, Cambodia, China, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.

Sales Milestone Event	Sales Milestone Payment
First achievement of annual Net Sales of Products in the GSK Territory greater than Two Hundred Million Dollars (\$200,000,000) up to and including Three Hundred Million Dollars (\$300,000,000)	\$25,000,000
First achievement of annual Net Sales of Products in the GSK Territory greater than Three Hundred Million Dollars (\$300,000,000) up to and including Four Hundred Million Dollars (\$400,000,000)	\$25,000,000
First achievement of annual Net Sales of Products in the GSK Territory greater than Four Hundred Million Dollars (\$400,000,000) up to and including Five Hundred Million Dollars (\$500,000,000)	\$25,000,000
First achievement of annual Net Sales of Products in the GSK Territory greater than Five Hundred Million Dollars (\$500,000,000) up to and including Seven Hundred and Fifty Million Dollars (\$750,000,000)	\$50,000,000
First achievement of annual Net Sales of Products in the GSK Territory greater than Seven Hundred and Fifty Million Dollars (\$750,000,000) up to and including One Billion Dollars (\$1,000,000,000)	\$50,000,000
First achievement of annual Net Sales of Products in the GSK Territory greater than One Billion Dollars (\$1,000,000,000)	\$50,000,000
Total Sales Milestone Payments:	\$225,000,000